- Home
- BRNS vs PULM Comparison
BRNS vs PULM Comparison
Compare BRNS & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- PULM
- Stock Information
- Founded
- BRNS 2016
- PULM 2003
- Country
- BRNS United Kingdom
- PULM United States
- Employees
- BRNS N/A
- PULM N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- PULM Health Care
- Exchange
- BRNS Nasdaq
- PULM Nasdaq
- Market Cap
- BRNS 28.2M
- PULM 30.9M
- IPO Year
- BRNS 2021
- PULM N/A
- Fundamental
- Price
- BRNS $0.84
- PULM $6.77
- Analyst Decision
- BRNS Strong Buy
- PULM
- Analyst Count
- BRNS 2
- PULM 0
- Target Price
- BRNS $3.00
- PULM N/A
- AVG Volume (30 Days)
- BRNS 25.3K
- PULM 17.2K
- Earning Date
- BRNS 05-12-2025
- PULM 05-09-2025
- Dividend Yield
- BRNS N/A
- PULM N/A
- EPS Growth
- BRNS N/A
- PULM N/A
- EPS
- BRNS N/A
- PULM N/A
- Revenue
- BRNS $14,969,000.00
- PULM $7,806,000.00
- Revenue This Year
- BRNS N/A
- PULM N/A
- Revenue Next Year
- BRNS N/A
- PULM $134.88
- P/E Ratio
- BRNS N/A
- PULM N/A
- Revenue Growth
- BRNS 1766.46
- PULM 6.96
- 52 Week Low
- BRNS $0.64
- PULM $1.72
- 52 Week High
- BRNS $2.60
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- BRNS 51.29
- PULM 56.26
- Support Level
- BRNS $0.68
- PULM $5.31
- Resistance Level
- BRNS $0.97
- PULM $6.52
- Average True Range (ATR)
- BRNS 0.08
- PULM 0.46
- MACD
- BRNS 0.02
- PULM 0.18
- Stochastic Oscillator
- BRNS 55.69
- PULM 99.40
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.